BE2013C034I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C034I2 BE2013C034I2 BE2013C034C BE2013C034C BE2013C034I2 BE 2013C034 I2 BE2013C034 I2 BE 2013C034I2 BE 2013C034 C BE2013C034 C BE 2013C034C BE 2013C034 C BE2013C034 C BE 2013C034C BE 2013C034 I2 BE2013C034 I2 BE 2013C034I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52859303P | 2003-12-11 | 2003-12-11 | |
US52859203P | 2003-12-11 | 2003-12-11 | |
US52876003P | 2003-12-11 | 2003-12-11 | |
US56089404P | 2004-04-09 | 2004-04-09 | |
US11/010,828 US8007826B2 (en) | 2003-12-11 | 2004-12-13 | Sustained release aminopyridine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2013C034I2 true BE2013C034I2 (de) | 2024-08-08 |
Family
ID=35460826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2013C034C BE2013C034I2 (de) | 2003-12-11 | 2013-06-07 |
Country Status (2)
Country | Link |
---|---|
US (46) | US8007826B2 (de) |
BE (1) | BE2013C034I2 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
US8795723B2 (en) * | 2005-09-09 | 2014-08-05 | Angelini Pharma Inc. | Sustained drug release compositions |
DE102007054702B4 (de) | 2007-11-14 | 2018-10-18 | Smartpolymer Gmbh | Verfahren zur Herstellung von cellulosischen Formkörpern, cellulosischer Formkörper und dessen Verwendung |
BRPI1000031A2 (pt) * | 2009-02-11 | 2018-02-14 | Acorda Therapeutics Inc | métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição |
JO3348B1 (ar) * | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
WO2011102505A1 (ja) * | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | 経口用徐放性固形製剤 |
EP2540294B1 (de) * | 2010-02-22 | 2016-08-03 | Daiichi Sankyo Company, Limited | Feststoffpräparat mit verzögerter freisetzung zur oralen verabreichung |
ES2706880T3 (es) | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
EP2629615B1 (de) | 2010-10-22 | 2018-10-10 | Duke University | Retardformulierungen aus 5-hydroxytryptophan als zusatz für pro-serotonergische therapien |
US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
EP2667869A1 (de) | 2011-01-28 | 2013-12-04 | Acorda Therapeutics, Inc. | Verwendung von kaliumkanalblockern zur behandlung von zerebralparese |
TWI592156B (zh) * | 2011-10-04 | 2017-07-21 | 艾可達醫療公司 | 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法 |
MX2014009811A (es) | 2012-02-13 | 2014-09-08 | Acorda Therapeutics Inc | Metodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis multiple que utilizan una aminopiridina. |
WO2014028387A1 (en) | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
TWI566786B (zh) | 2012-09-03 | 2017-01-21 | 第一三共股份有限公司 | 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物 |
WO2014093475A1 (en) | 2012-12-11 | 2014-06-19 | Acorda Therapeutics, Inc. | Methods for treating parkinson's disease using aminopyridines |
CN107501110B (zh) | 2013-03-14 | 2020-05-05 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
WO2014151752A1 (en) | 2013-03-15 | 2014-09-25 | University Of Rochester | Composition and methods for the treatment of peripheral nerve injury |
EP3427735A1 (de) | 2013-04-15 | 2019-01-16 | Acorda Therapeutics, Inc. | Verfahren zur behandlung von sensomotorischen störungen im zusammenhang mit bestimmten typen von schlaganfall mithilfe von aminopyridinen |
SG11201705124QA (en) | 2015-02-08 | 2017-07-28 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
US10411512B2 (en) * | 2015-04-10 | 2019-09-10 | Qualcomm Incorporated | Methods and apparatus for implementing presence and usage pattern detection in wireless charging applications |
RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
TWI679012B (zh) | 2015-09-11 | 2019-12-11 | 法德生技藥品股份有限公司 | 含有達方吡啶的緩釋口服滲透錠劑及其用途 |
WO2018186866A1 (en) * | 2017-04-06 | 2018-10-11 | Cobb Joseph E Jr | Sustained release compositions of 4-aminopyridine |
CN106551914A (zh) * | 2015-09-29 | 2017-04-05 | 深圳翰宇药业股份有限公司 | 一种达方吡啶缓释片及其制备方法 |
WO2017058869A1 (en) | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
US10888552B2 (en) * | 2016-08-12 | 2021-01-12 | Steven Rothman | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability |
US11583542B2 (en) * | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
CH415963A (de) | 1964-09-04 | 1966-06-30 | Wander Ag Dr A | Masse zur Herstellung von Tabletten mit protrahierter Wirkung |
US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
US4508715A (en) * | 1981-07-01 | 1985-04-02 | University Of Georgia Research Foundation, Inc. | Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs |
US4386095A (en) * | 1982-02-22 | 1983-05-31 | Cornell Research Foundation, Inc. | Diaminopyridines to improve cognition |
IE53703B1 (en) | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
IE54286B1 (en) | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
US4851230A (en) * | 1983-04-07 | 1989-07-25 | Bristol-Myers Company | Capsule shaped tablets |
IE56459B1 (en) | 1983-12-21 | 1991-08-14 | Elan Corp Ltd | Controlled absorption pharmaceutical formulation |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4894240A (en) * | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
US4562196A (en) | 1984-04-06 | 1985-12-31 | Nelson Research & Development | 2,4-Diaminopyridine as a pharmacologic agent |
JPS6124516A (ja) | 1984-07-12 | 1986-02-03 | Fujisawa Pharmaceut Co Ltd | 持続性錠剤 |
US4812447A (en) | 1985-10-22 | 1989-03-14 | City Of Hope | Method for the treatment of nervous system degeneration |
US4760092A (en) | 1985-10-29 | 1988-07-26 | The Rockefeller University | Treatment of demyelinating diseases |
US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
IL86170A (en) * | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
FI895821A0 (fi) * | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
US4948581A (en) | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
TW200462B (de) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
CA2085785C (en) | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5952357A (en) * | 1993-12-23 | 1999-09-14 | Cornell Research Foundation, Inc. | Treating diseases of the anterior horn cells |
US6284473B1 (en) * | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
GB2356585B (en) * | 1996-11-13 | 2001-07-11 | Phoqus Ltd | Method and apparatus for the coating of substrates for pharmaceutical use and intermediate products for use in producing solid dosage forms |
US7179486B1 (en) * | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
WO2004082684A1 (en) | 2003-03-17 | 2004-09-30 | Acorda Therapeutics | Stable oral formulations of aminopyridines and uses thereof |
US20070037848A1 (en) * | 2003-04-03 | 2007-02-15 | Masters Colin L | Treatment of neurological conditions |
CA2534711A1 (en) * | 2003-08-01 | 2005-02-10 | Medarex, Inc. | Combination therapies for multiple sclerosis |
US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
US20060276537A1 (en) * | 2005-06-01 | 2006-12-07 | Tamar Goren | Use of ladostigil for the treatment of multiple sclerosis |
CA2623955C (en) * | 2005-09-23 | 2019-12-17 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
US20100166187A1 (en) * | 2006-09-11 | 2010-07-01 | Alexei Trifonov | Qkd using high-altitude paltforms |
EP2343976A4 (de) | 2008-09-10 | 2011-12-14 | Acorda Therapeutics Inc | Verfahren zur verwendung von aminopyridinzusammensetzungen mit verzögerter freisetzung |
WO2010090730A1 (en) | 2009-02-03 | 2010-08-12 | Acorda Therapeutics, Inc. | Method, apparatus and software for identifying responders in a clinical environment |
BRPI1000031A2 (pt) | 2009-02-11 | 2018-02-14 | Acorda Therapeutics Inc | métodos para tratar de modo durável a esclerose múltipla em um paciente, para tratar eficazmente a esclerose múltipla em um paciente em um período de tempo crônico, para aumentar a capacidade de caminhar e para tratar os sintomas de esclerose múltipla, e, composição |
TWM368960U (en) * | 2009-06-26 | 2009-11-11 | Jin-Chang Guo | Cable winder structure |
JO3348B1 (ar) | 2009-08-11 | 2019-03-13 | Acorda Therapeutics Inc | استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي |
TW201125562A (en) | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
-
2004
- 2004-12-13 US US11/010,828 patent/US8007826B2/en active Active
-
2009
- 2009-11-25 US US12/626,085 patent/US20100272796A1/en not_active Abandoned
- 2009-11-25 US US12/626,001 patent/US20100272807A1/en not_active Abandoned
- 2009-11-25 US US12/626,036 patent/US20100272795A1/en not_active Abandoned
-
2010
- 2010-06-25 US US12/824,140 patent/US20100324099A1/en not_active Abandoned
- 2010-06-25 US US12/824,141 patent/US20100324100A1/en not_active Abandoned
- 2010-06-25 US US12/824,137 patent/US20100324098A1/en not_active Abandoned
-
2011
- 2011-07-20 US US13/187,158 patent/US8663685B2/en active Active
-
2012
- 2012-08-14 US US13/585,277 patent/US20130045276A1/en not_active Abandoned
-
2013
- 2013-06-07 BE BE2013C034C patent/BE2013C034I2/nl unknown
- 2013-07-24 US US13/949,889 patent/US20130310426A1/en not_active Abandoned
- 2013-09-12 US US14/025,248 patent/US20140018397A1/en not_active Abandoned
-
2015
- 2015-12-04 US US14/960,126 patent/US20160081992A1/en not_active Abandoned
-
2016
- 2016-03-02 US US15/058,785 patent/US20160175294A1/en not_active Abandoned
- 2016-07-15 US US15/211,590 patent/US20160324840A1/en not_active Abandoned
- 2016-10-14 US US15/294,266 patent/US20170027874A1/en not_active Abandoned
-
2017
- 2017-02-24 US US15/442,017 patent/US20170165245A1/en not_active Abandoned
- 2017-04-07 US US15/482,412 patent/US9918973B2/en active Active
- 2017-05-26 US US15/606,906 patent/US20170258730A1/en not_active Abandoned
- 2017-11-02 US US15/801,409 patent/US20180055774A1/en not_active Abandoned
-
2018
- 2018-01-05 US US15/863,835 patent/US20180125790A1/en not_active Abandoned
- 2018-01-29 US US15/882,804 patent/US20180153869A1/en not_active Abandoned
- 2018-05-16 US US15/981,600 patent/US20180256555A1/en not_active Abandoned
- 2018-08-29 US US16/116,331 patent/US20180369216A1/en not_active Abandoned
- 2018-09-24 US US16/139,992 patent/US20190022076A1/en not_active Abandoned
-
2019
- 2019-01-04 US US16/240,682 patent/US20190134015A1/en not_active Abandoned
- 2019-02-27 US US16/287,575 patent/US20190231763A1/en not_active Abandoned
- 2019-04-17 US US16/387,504 patent/US20190240206A1/en not_active Abandoned
- 2019-08-29 US US16/555,727 patent/US20190381020A1/en not_active Abandoned
- 2019-11-25 US US16/695,024 patent/US20200093809A1/en not_active Abandoned
-
2020
- 2020-04-08 US US16/843,750 patent/US20200230122A1/en not_active Abandoned
- 2020-07-10 US US16/926,549 patent/US20200338053A1/en not_active Abandoned
- 2020-08-12 US US16/991,909 patent/US20200368217A1/en not_active Abandoned
- 2020-11-12 US US17/096,849 patent/US20210059996A1/en not_active Abandoned
-
2021
- 2021-03-16 US US17/203,519 patent/US20210205282A1/en not_active Abandoned
- 2021-06-21 US US17/353,660 patent/US20210308112A1/en not_active Abandoned
- 2021-09-30 US US17/491,330 patent/US20220016094A1/en not_active Abandoned
- 2021-10-26 US US17/511,223 patent/US20220040161A1/en not_active Abandoned
-
2022
- 2022-01-28 US US17/588,133 patent/US20220142999A1/en not_active Abandoned
- 2022-05-12 US US17/743,258 patent/US20220265624A1/en active Pending
- 2022-06-02 US US17/831,209 patent/US20220296577A1/en not_active Abandoned
- 2022-06-22 US US17/808,234 patent/US11786514B2/en active Active
- 2022-12-29 US US18/090,926 patent/US20230133230A1/en not_active Abandoned
-
2023
- 2023-04-18 US US18/136,120 patent/US20230293505A1/en not_active Abandoned
- 2023-08-23 US US18/237,330 patent/US20230390261A1/en not_active Abandoned
- 2023-10-16 US US18/487,671 patent/US20240058313A1/en active Pending
-
2024
- 2024-01-12 US US18/412,248 patent/US20240156794A1/en active Pending